Across
- 3. GLP1 & GIP are exampple of _____ hormone
- 5. Evogliptin reaches ______ state concentration within 3 days of therapy
- 7. In Valera M we have used ____ technology
- 8. As per a recently published data on 29000 Type 2 Diabetes patients, there was _______ fold increased risk of CVD with high Glycaemic Variability.
- 9. With the help of _______ test we can measure Glycaemic variability
- 10. Galvas contains_______
Down
- 1. Evogliotin shows >80% DPP4 ______ at the end of 24 hours also
- 2. Valera can be safely prescribed in renal patients until the _____ in 15 ml/min.
- 4. Glycaemic Variability is one of the major concern for Diabetes related ______
- 6. As per _______ India study, Evogliptin 5 mg was effective, safe and non-inferior to Sitagliptin as an add on therapy to Metformin 1000mg in Indian patients with T2DM.
- 8. is the brand of Linagliptin by Boheringer Ingelheim
- 9. Evogliptin is found safe in _____ patients because it is excreted majorly by hepatic